Funder
Tsumura and Company
Japan Society for the Promotion of Science
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Alzheimer’s Association (2018) Alzheimer’s disease facts and figures. Alzheimer’s Dement. 14:367–429. https://doi.org/10.1016/j.jalz.2018.02.001
2. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189. https://doi.org/10.1101/cshperspect.a006189
3. Shi M, Chu F, Zhu F, Zhu J (2022) Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on Aducanumab and Lecanemab. Front Aging Neurosci 14:870517. https://doi.org/10.3389/fnagi.2022.870517
4. Decourt B, Boumelhem F, Pope ED 3rd, Shi J, Mari Z, Sabbagh MN (2021) Critical appraisal of amyloid lowering agents in AD. Curr Neurol Neurosci Rep 21(8):39. https://doi.org/10.1007/s11910-021-01125-y
5. Nogami-Hara A, Kubota K, Takasaki K, Watanabe T, Egahira N, Iba H, Fujikawa R, Katsurabayashi S, Funda Bolukbasi H, Izzettin H-A-K, Iwasaki K (2019) Extract of Yokukansan improves anxiety-like behavior and increases serum brain-derived neurotrophic factor in rats with cerebral ischemia combined with amyloid-42 peptide. J Tradit Chin Med 39(1):50–58